Patients with nasopharyngeal carcinoma often experience weight loss and tumor regression
during the course of radiotherapy that lasts for up to 6–7 weeks. Adaptive radiotherapy is a …

Opinion statement Nasopharyngeal carcinoma (NPC) is a rare malignancy, endemic in
China, that is commonly diagnosed in locally advanced scenarios. Its pathogenesis is …

Background Previous studies demonstrated that induction chemotherapy (IC) followed by de-
escalated chemoradiotherapy adapted to tumor response was effective in treating childhood …

The antiangiogenic agent apatinib has been shown to clinically improve responses to
immune checkpoint inhibitors in several cancer types. Patients with N3 nasopharyngeal …

Background and objectives Gemcitabine plus cisplatin (GP) and docetaxel plus cisplatin
plus fluorouracil (TPF) are induction chemotherapy (IC) regimens for locally advanced …

Chemotherapeutic resistance is one of the most common reasons for poor prognosis of
patients with nasopharyngeal carcinoma (NPC). We found that CENPN can promote the …

Background: The standard of care for locoregionally advanced nasopharyngeal carcinoma
(LA-NPC) is induction chemotherapy (ICT) followed by concurrent chemoradiation (CCRT) …

The glycocalyx—that forms a protective barrier around cells—has been implicated in cancer
cell proliferation, survival, and metastasis. However, its role in maintaining the integrity of …

Background To examine the prognostic relevance of pan-immune-inflammation value (PIV)
in locally advanced nasopharyngeal carcinomas (LA-NPC) patients treated with concurrent …

Nasopharyngeal carcinoma (NPC) is the most interesting and intriguing malignant tumour
located in the nasopharynx, because it is a “peculiar” malignancy,“different” from almost all …